Getein Biotech, Inc (SHA:603387)
China · Delayed Price · Currency is CNY 9.09
-0.25 (-2.68%)
May 21, 2026, 3:00 PM CST
Getein Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,075 | 1,052 | 1,149 | 1,355 | 1,816 | 1,398 |
Other Revenue | - | - | 15.58 | 14.45 | 6.18 | 3.62 |
| 1,075 | 1,052 | 1,165 | 1,369 | 1,822 | 1,402 | |
Revenue Growth (YoY) | -1.13% | -9.71% | -14.93% | -24.85% | 29.98% | 24.78% |
Cost of Revenue | 341.26 | 317.73 | 374.39 | 479.71 | 671.56 | 485.42 |
Gross Profit | 733.8 | 733.99 | 790.41 | 889.45 | 1,150 | 916.29 |
Selling, General & Admin | 320.81 | 322.45 | 371.6 | 439.87 | 407.26 | 324.08 |
Research & Development | 155.3 | 157.4 | 181.21 | 217.99 | 223.22 | 163.39 |
Other Operating Expenses | -9.38 | -2.87 | 3.17 | 0.14 | -0.07 | 12.55 |
Operating Expenses | 463.73 | 476.98 | 569.68 | 677.22 | 653.29 | 506.69 |
Operating Income | 270.07 | 257.01 | 220.73 | 212.24 | 497.01 | 409.59 |
Interest Expense | -2.61 | - | -14.93 | -16.94 | -16.61 | -14.31 |
Interest & Investment Income | 1.23 | - | 45.79 | 72.02 | 45.5 | 47.97 |
Currency Exchange Gain (Loss) | - | - | 5.8 | 11.31 | 19.41 | -0.97 |
Other Non Operating Income (Expenses) | -20.04 | -18.88 | -0.49 | -0.54 | -3.29 | -4.42 |
EBT Excluding Unusual Items | 248.65 | 238.13 | 256.9 | 278.09 | 542.03 | 437.86 |
Impairment of Goodwill | - | - | -25.83 | - | - | - |
Gain (Loss) on Sale of Investments | 19.7 | 18.29 | 0.15 | 10.25 | 18.46 | -4.29 |
Gain (Loss) on Sale of Assets | -0.1 | -0.05 | 1.59 | 0.67 | 0.02 | 0.95 |
Asset Writedown | -27.22 | -28.68 | -5.32 | -1.69 | -0.53 | - |
Other Unusual Items | - | - | 25.93 | 17.63 | - | 17.11 |
Pretax Income | 241.03 | 227.69 | 253.43 | 304.94 | 559.98 | 451.63 |
Income Tax Expense | 18.17 | 15.77 | 23.55 | 20.86 | 56.03 | 39.62 |
Earnings From Continuing Operations | 222.86 | 211.92 | 229.88 | 284.08 | 503.94 | 412.01 |
Minority Interest in Earnings | 9.8 | 8.74 | -6.24 | -4.31 | -5.03 | -13.02 |
Net Income | 232.66 | 220.66 | 223.64 | 279.77 | 498.91 | 398.99 |
Net Income to Common | 232.66 | 220.66 | 223.64 | 279.77 | 498.91 | 398.99 |
Net Income Growth | 15.22% | -1.33% | -20.06% | -43.92% | 25.04% | 30.93% |
Shares Outstanding (Basic) | 505 | 502 | 508 | 509 | 509 | 505 |
Shares Outstanding (Diluted) | 505 | 502 | 508 | 509 | 509 | 512 |
Shares Change (YoY) | -0.09% | -1.33% | -0.08% | -0.08% | -0.48% | 0.72% |
EPS (Basic) | 0.46 | 0.44 | 0.44 | 0.55 | 0.98 | 0.79 |
EPS (Diluted) | 0.46 | 0.44 | 0.44 | 0.55 | 0.98 | 0.78 |
EPS Growth | 15.32% | - | -20.00% | -43.88% | 25.64% | 30.00% |
Free Cash Flow | 281.25 | 242.01 | 266.6 | 75.09 | 265.51 | 252.77 |
Free Cash Flow Per Share | 0.56 | 0.48 | 0.53 | 0.15 | 0.52 | 0.49 |
Dividend Per Share | - | - | 0.180 | 0.200 | 0.340 | 0.243 |
Dividend Growth | - | - | -10.00% | -41.18% | 39.98% | 32.30% |
Gross Margin | 68.26% | 69.79% | 67.86% | 64.96% | 63.14% | 65.37% |
Operating Margin | 25.12% | 24.44% | 18.95% | 15.50% | 27.28% | 29.22% |
Profit Margin | 21.64% | 20.98% | 19.20% | 20.43% | 27.38% | 28.46% |
Free Cash Flow Margin | 26.16% | 23.01% | 22.89% | 5.49% | 14.57% | 18.03% |
EBITDA | 353.09 | 340.6 | 306.61 | 297.73 | 561.95 | 457.04 |
EBITDA Margin | 32.84% | 32.39% | 26.32% | 21.75% | 30.84% | 32.61% |
D&A For EBITDA | 83.02 | 83.59 | 85.88 | 85.49 | 64.93 | 47.44 |
EBIT | 270.07 | 257.01 | 220.73 | 212.24 | 497.01 | 409.59 |
EBIT Margin | 25.12% | 24.44% | 18.95% | 15.50% | 27.28% | 29.22% |
Effective Tax Rate | 7.54% | 6.93% | 9.29% | 6.84% | 10.01% | 8.77% |
Revenue as Reported | 23.35 | - | 1,165 | 1,369 | 1,822 | 1,402 |
Advertising Expenses | - | - | 20.46 | 43.56 | 47.32 | 36.19 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.